Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 35, 2024 - Issue 1
Submit an article Journal homepage
847
Views
0
CrossRef citations to date
0
Altmetric
Case Report

Use of a topical Janus kinase inhibitor in immune checkpoint inhibitor-induced eczematous reaction: a case report

Camille M. Powersa Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USAORCID Iconhttps://orcid.org/0000-0003-2106-0566
ORCID Icon,
Hannah Vermaa Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
,
Jeremy Orloffa Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
,
Austin J. Piontkowskia Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
,
Amy Tierstenb Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
,
Angela Lamba Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
&
Nicholas Gulatia Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USACorrespondence[email protected]
 show all
Article: 2336118 | Received 29 Feb 2024, Accepted 22 Mar 2024, Published online: 02 Apr 2024

References

  • Nikolaou V, Tsimpidakis A, Stratigos A. Cutaneous adverse reactions of immunotherapy in patients with advanced melanoma. Cancers (Basel). Mar 31 2023;15(7):2084. doi: 10.3390/cancers15072084.
  • Phillips GS, Wu J, Hellmann MD, et al. Treatment outcomes of immune-related cutaneous adverse events. J Clin Oncol. Oct 20 2019;37(30):2746–2758. doi: 10.1200/JCO.18.02141.
  • Henderson Berg M-H, Del Rincón SV, Miller WH. Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition. J Immunother Cancer. Jan 2022;10(1):e003551. doi: 10.1136/jitc-2021-003551.
  • Reschke R, Shapiro JW, Yu J, et al. Checkpoint blockade-induced dermatitis and colitis are dominated by tissue-resident memory T cells and Th1/Tc1 cytokines. Cancer Immunol Res. Oct 4 2022;10(10):1167–1174. doi: 10.1158/2326-6066.CIR-22-0362.
  • Kim HS, Kwon JE, Park YJ. Atezolizumab plus bevacizumab-induced recalcitrant pyoderma gangrenosum treated with baricitinib: a case report. Acta Derm Venereol. Aug 1 2023;103:adv9646. doi: 10.2340/actadv.v103.9646.
  • Chen CY, Chiu CF, Bai LY. Treatment of pembrolizumab-induced cutaneous lesions with ruxolitinib. Eur J Cancer. May 2019;113:69–71. doi: 10.1016/j.ejca.2019.03.016.
  • Brunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. Apr 2017;139(4S):S65–S76. doi: 10.1016/j.jaci.2017.01.011.
  • Seif F, Khoshmirsafa M, Aazami H, et al. The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. Cell Commun Signal. Jun 21 2017;15(1):23. doi: 10.1186/s12964-017-0177-y.
  • Bissonnette R, Call RS, Raoof T, et al. A maximum-use trial of ruxolitinib cream in adolescents and adults with atopic dermatitis. Am J Clin Dermatol. May 2022;23(3):355–364. doi: 10.1007/s40257-022-00690-3.
  • Reschke R, Gajewski TF. Tissue-resident memory T cells in immune-related adverse events: friend or foe? Oncoimmunology. 2023;12(1):2197358. doi: 10.1080/2162402X.2023.2197358.
  • Ytterberg SR, Bhatt DL, Connell CA. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. Reply. N Engl J Med. May 5 2022;386(18):1768–1326. doi: 10.1056/NEJMc2202778.
  • Ingrassia JP, Maqsood MH, Gelfand JM, et al. Cardiovascular and venous thromboembolic risk with JAK inhibitors in immune-mediated inflammatory skin diseases: a systematic review and Meta-Analysis. JAMA Dermatol. 2023;160(1):28–36. Nov 1 doi: 10.1001/jamadermatol.2023.4090.
  • Chen CH, Yu HS, Yu S. Cutaneous adverse events associated with immune checkpoint inhibitors: a review article. Curr Oncol. Apr 18 2022;29(4):2871–2886. doi: 10.3390/curroncol29040234.
  • Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. Oct 2021;85(4):863–872. doi: 10.1016/j.jaad.2021.04.085.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.